V Castel, A Cañete, C Melero, T Acha, A Navajas, P García-Miguel, T Contra, J Molina, P Galarón, O Cruz
{"title":"转移性复发和难治性神经母细胞瘤的合作方案(N-III-95)的结果。","authors":"V Castel, A Cañete, C Melero, T Acha, A Navajas, P García-Miguel, T Contra, J Molina, P Galarón, O Cruz","doi":"10.1002/1096-911x(20001201)35:6<724::aid-mpo53>3.0.co;2-u","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Prognosis of relapsed and refractory neuroblastoma is uniformly fatal; new therapeutic approaches are needed.</p><p><strong>Procedure: </strong>Relapsed and refractory neuroblastoma patients were treated with continuous infusion chemotherapy combined with MIBG.</p><p><strong>Results: </strong>Over 4 years, 35 heavily pretreated patients were registered, 29 with bone or/and bone marrow metastases. Grade 3 or 4 hematologic toxicity was frequent, without toxic deaths. Sixteen patients responded. The probability of 5-year overall survival was 0.19.</p><p><strong>Conclusions: </strong>This approach is feasible and toxicity manageable; it rescued some patients and prolonged their survival. It merits assay in newly diagnosed high-risk neuroblastoma patients.</p>","PeriodicalId":18531,"journal":{"name":"Medical and pediatric oncology","volume":"35 6","pages":"724-6"},"PeriodicalIF":0.0000,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/1096-911x(20001201)35:6<724::aid-mpo53>3.0.co;2-u","citationCount":"10","resultStr":"{\"title\":\"Results of the cooperative protocol (N-III-95) for metastatic relapses and refractory neuroblastoma.\",\"authors\":\"V Castel, A Cañete, C Melero, T Acha, A Navajas, P García-Miguel, T Contra, J Molina, P Galarón, O Cruz\",\"doi\":\"10.1002/1096-911x(20001201)35:6<724::aid-mpo53>3.0.co;2-u\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Prognosis of relapsed and refractory neuroblastoma is uniformly fatal; new therapeutic approaches are needed.</p><p><strong>Procedure: </strong>Relapsed and refractory neuroblastoma patients were treated with continuous infusion chemotherapy combined with MIBG.</p><p><strong>Results: </strong>Over 4 years, 35 heavily pretreated patients were registered, 29 with bone or/and bone marrow metastases. Grade 3 or 4 hematologic toxicity was frequent, without toxic deaths. Sixteen patients responded. The probability of 5-year overall survival was 0.19.</p><p><strong>Conclusions: </strong>This approach is feasible and toxicity manageable; it rescued some patients and prolonged their survival. It merits assay in newly diagnosed high-risk neuroblastoma patients.</p>\",\"PeriodicalId\":18531,\"journal\":{\"name\":\"Medical and pediatric oncology\",\"volume\":\"35 6\",\"pages\":\"724-6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2000-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/1096-911x(20001201)35:6<724::aid-mpo53>3.0.co;2-u\",\"citationCount\":\"10\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical and pediatric oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/1096-911x(20001201)35:6<724::aid-mpo53>3.0.co;2-u\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical and pediatric oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/1096-911x(20001201)35:6<724::aid-mpo53>3.0.co;2-u","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Results of the cooperative protocol (N-III-95) for metastatic relapses and refractory neuroblastoma.
Background: Prognosis of relapsed and refractory neuroblastoma is uniformly fatal; new therapeutic approaches are needed.
Procedure: Relapsed and refractory neuroblastoma patients were treated with continuous infusion chemotherapy combined with MIBG.
Results: Over 4 years, 35 heavily pretreated patients were registered, 29 with bone or/and bone marrow metastases. Grade 3 or 4 hematologic toxicity was frequent, without toxic deaths. Sixteen patients responded. The probability of 5-year overall survival was 0.19.
Conclusions: This approach is feasible and toxicity manageable; it rescued some patients and prolonged their survival. It merits assay in newly diagnosed high-risk neuroblastoma patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
